Shire snaffles Dyax for $5.9bn plus kicker for HAE drug
Shire, the UK pharmaceutical company, has agreed to acquire US biopharmaceuticals company Dyax for $5.9bn in cash. Deutsche Bank and Morgan Stanley are arranging financing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts